- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07225946
Um Estudo de Pasritamig com Docetaxel versus Docetaxel em Participantes com Cancro da Próstata Metastático Resistente à Castração (KLK2-PASenger)
Um Estudo de Fase 3 Randomizado, Aberto de Pasritamig (JNJ-78278343), um Agente de Redirecionamento de Células T que Tem como Alvo a Calicreína 2 Humana, com Docetaxel versus Docetaxel para Cancro da Próstata Metastático Resistente à Castração
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Study Contact
- Número de telefone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Locais de estudo
-
-
-
Dresden, Alemanha, 01307
- Recrutamento
- Universitatsklinikum Carl Gustav Carus Dresden
-
Duisburg, Alemanha, 47169
- Recrutamento
- Urologicum Duisburg
-
Essen, Alemanha, 45147
- Recrutamento
- Universitaetsklinikum Essen
-
Hamburg, Alemanha, 20246
- Recrutamento
- Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
-
München, Alemanha, 81675
- Recrutamento
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Nürtingen, Alemanha, 72622
- Recrutamento
- Studienpraxis Urologie Drs. Feyerabend
-
-
-
-
-
Heidelberg, Austrália, 3084
- Recrutamento
- Warringal Private Hospital
-
Kurralta Park, Austrália, 5037
- Recrutamento
- Icon Cancer Centre Kurralta Park
-
Melbourne, Austrália, 3000
- Recrutamento
- Peter MacCallum Cancer Centre
-
Wahroonga, Austrália, 2076
- Recrutamento
- Sydney Adventist Hospital
-
Woolloongabba, Austrália, 4102
- Recrutamento
- Princess Alexandra Hospital
-
-
-
-
-
Bauru, Brasil, 17033-495
- Recrutamento
- NAIC Nair Antunes Instituto do Cancer
-
Natal, Brasil, 59062 000
- Recrutamento
- Liga Norte Riograndense Contra O Cancer
-
Santa Cruz do Sul, Brasil, 96835-100
- Recrutamento
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André, Brasil, 09060 870
- Recrutamento
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasil, 01243 020
- Recrutamento
- Hospital Samaritano de Sao Paulo
-
-
-
-
-
Aalst, Bélgica, 9300
- Recrutamento
- AZORG campus Aalst Moorselbaan
-
Antwerp, Bélgica, 2610
- Recrutamento
- ZAS Augustinus
-
Ghent, Bélgica, 9000
- Recrutamento
- AZ Maria Middelares
-
La Louvière, Bélgica, 7100
- Recrutamento
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, Bélgica, 4000
- Recrutamento
- CHC MontLegia
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z4E6
- Recrutamento
- British Columbia Cancer Agency
-
Victoria, British Columbia, Canadá, V8R 6V5
- Recrutamento
- British Columbia Cancer Agency Vancouver Island Centre
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 8L6
- Recrutamento
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Canadá, M5G 2C4
- Recrutamento
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 0A9
- Recrutamento
- Centre de Recherche du CHUM
-
Québec, Quebec, Canadá, G1R 2J6
- Recrutamento
- CHU de Quebec Universite Laval
-
-
-
-
-
Beijing, China, 100142
- Recrutamento
- Beijing Cancer Hospital
-
Beijing, China, 100034
- Recrutamento
- Peking University First Hospital
-
Beijing, China, 101100
- Recrutamento
- Beijing Luhe Hospital, Capital Medical University
-
Chengdu, China, 610014
- Recrutamento
- The Third People's Hospital of Chengdu
-
Chengdu, China, 610041
- Recrutamento
- West China Hospital Sichuan University
-
Chongqing, China, 400030
- Recrutamento
- Chongqing University Cancer Hospital
-
Guangzhou, China, 510120
- Recrutamento
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, China, 510060
- Recrutamento
- Sun Yat Sen University Cancer Center
-
Hangzhou, China, 310009
- Recrutamento
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing, China, 210009
- Recrutamento
- Nanjing Drum Tower Hospital
-
Shanghai, China, 200080
- Recrutamento
- Shanghai General Hospital
-
Shanghai, China, 200031
- Recrutamento
- Huashan Hospital Fudan University
-
Shanghai, China, 200082
- Recrutamento
- Xinhua hospital,Shanghai Jiaotong University
-
Tianjin, China, 300211
- Recrutamento
- The Second Hospital Of Tianjin Medical University
-
Wuhan, China, 430014
- Recrutamento
- The Central Hospital of Wuhan
-
Xi'an, China, 710061
- Recrutamento
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Goyang-si, Coréia do Sul, 10408
- Recrutamento
- National Cancer Center
-
Seoul, Coréia do Sul, 05505
- Recrutamento
- Asan Medical Center
-
Seoul, Coréia do Sul, 06351
- Recrutamento
- Samsung Medical Center
-
Seoul, Coréia do Sul, 03722
- Recrutamento
- Severance Hospital Yonsei University Health System
-
Seoul, Coréia do Sul, 06591
- Recrutamento
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Badalona, Espanha, 08916
- Recrutamento
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, Espanha, 28034
- Recrutamento
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Espanha, 28041
- Recrutamento
- Hosp. Univ. 12 de Octubre
-
Murcia, Espanha, 30008
- Recrutamento
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Seville, Espanha, 41009
- Recrutamento
- Hosp. Virgen Macarena
-
Valencia, Espanha, 46014
- Recrutamento
- Hosp. Gral. Univ. Valencia
-
Zaragoza, Espanha, 50009
- Recrutamento
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85225
- Recrutamento
- Arizona Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Recrutamento
- Arkansas Urology
-
Springdale, Arkansas, Estados Unidos, 72762
- Recrutamento
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, Estados Unidos, 92708
- Recrutamento
- MemorialCare Orange Coast Medical Center
-
La Jolla, California, Estados Unidos, 92037
- Recrutamento
- University Of California San Diego
-
Los Alamitos, California, Estados Unidos, 90720
- Recrutamento
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Estados Unidos, 90033
- Recrutamento
- USC Norris Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90095
- Recrutamento
- Ronald Reagan UCLA Medical Center
-
Los Angeles, California, Estados Unidos, 90067
- Recrutamento
- Valkyrie Clinical Trials
-
Riverside, California, Estados Unidos, 92505
- Recrutamento
- Kaiser Permanente Southern California
-
San Diego, California, Estados Unidos, 92123
- Recrutamento
- Sharp Center for Research
-
Santa Monica, California, Estados Unidos, 90404
- Recrutamento
- Providence Saint John s Health Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Recrutamento
- Rocky Mountain Cancer Centers
-
Denver, Colorado, Estados Unidos, 80210
- Recrutamento
- AdventHealth Porter Oncology Research
-
Edwards, Colorado, Estados Unidos, 81632
- Recrutamento
- Vail Health Shaw Cancer Center
-
Grand Junction, Colorado, Estados Unidos, 81505
- Recrutamento
- Grand Valley Oncology
-
Lakewood, Colorado, Estados Unidos, 80228
- Recrutamento
- Colorado Clinical Research
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32803
- Recrutamento
- AdventHealth Orlando
-
Pembroke Pines, Florida, Estados Unidos, 33026
- Recrutamento
- Memorial Cancer Institute
-
Sarasota, Florida, Estados Unidos, 34232
- Recrutamento
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Winship Cancer Institute Emory University
-
-
Illinois
-
Lisle, Illinois, Estados Unidos, 60532
- Recrutamento
- Duly Health and Care
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Recrutamento
- Cancer Center of Kansas Heritage Plaza Medical Building
-
-
Kentucky
-
Edgewood, Kentucky, Estados Unidos, 41017
- Recrutamento
- St Elizabeth Healthcare
-
Louisville, Kentucky, Estados Unidos, 40207
- Recrutamento
- Norton Cancer Institute
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Recrutamento
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins Hospital
-
Baltimore, Maryland, Estados Unidos, 21201
- Recrutamento
- University of Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins Medical Institutions
-
Bethesda, Maryland, Estados Unidos, 20817
- Recrutamento
- Center for Cancer and Blood Disorders
-
Towson, Maryland, Estados Unidos, 21204
- Recrutamento
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Massachusetts General
-
-
Michigan
-
Sterling Heights, Michigan, Estados Unidos, 48314
- Recrutamento
- Profound Research LLC at Cancer and Leukemia Center
-
-
Minnesota
-
Saint Louis Park, Minnesota, Estados Unidos, 55426
- Recrutamento
- HealthPartners Frauenshuh Cancer Center CRC West
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Recrutamento
- HealthPartners Cancer Center at Regions Hospital CRC East
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Recrutamento
- University of Mississippi Medical Center
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- Washington University
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68506
- Recrutamento
- NHO Revive Research Institute, LLC
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Recrutamento
- Cooper Health System MD Anderson Cancer Center at Cooper
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Recrutamento
- Astera Cancer Care
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Recrutamento
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola, New York, Estados Unidos, 11501
- Recrutamento
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, Estados Unidos, 10016
- Recrutamento
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
The Bronx, New York, Estados Unidos, 10461
- Recrutamento
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke University Medical Center
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Recrutamento
- Gabrail Cancer Center
-
Cincinnati, Ohio, Estados Unidos, 45219
- Recrutamento
- University of Cincinnati
-
Cleveland, Ohio, Estados Unidos, 44109
- Recrutamento
- Metrohealth Medical Center
-
-
Oregon
-
Springfield, Oregon, Estados Unidos, 97477
- Recrutamento
- Oregon Urology Institute
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Recrutamento
- Lehigh Valley Hospital
-
Bala-Cynwyd, Pennsylvania, Estados Unidos, 19004
- Recrutamento
- MidLantic Urology
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Recrutamento
- Penn State Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Recrutamento
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Recrutamento
- Carolina Urologic Research Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Recrutamento
- Avera Medical Group
-
Watertown, South Dakota, Estados Unidos, 57201
- Recrutamento
- Prairie Lakes Health Care System
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37909
- Recrutamento
- Tennessee Cancer Specialists
-
-
Texas
-
Austin, Texas, Estados Unidos, 78731
- Recrutamento
- Texas Oncology
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- UT Southwestern Medical Center
-
Houston, Texas, Estados Unidos, 77027
- Recrutamento
- Houston Metro Urology
-
Sugar Land, Texas, Estados Unidos, 77479
- Recrutamento
- Texas Oncology 1
-
The Woodlands, Texas, Estados Unidos, 77380
- Recrutamento
- Renovatio Clinical
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- Virginia Cancer Specialists
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- Fred Hutch Cancer Center Sloan Clinic 2
-
-
-
-
-
Bordeaux, França, 33076
- Recrutamento
- Institut Bergonie
-
Clermont-Ferrand, França, 63011
- Recrutamento
- Centre Jean Perrin
-
Lille, França, 59000
- Recrutamento
- Centre Oscar Lambret
-
Lyon, França, 69008
- Recrutamento
- Centre Leon Berard
-
Nîmes, França, 30900
- Recrutamento
- Groupe Hospitalo-Universitaire Carémeau
-
Paris, França, 75908
- Recrutamento
- Hopital Europeen Georges-Pompidou
-
Rennes, França, 35062
- Recrutamento
- Centre Eugene Marquis
-
Villejuif, França, 94800
- Recrutamento
- Gustave Roussy
-
-
-
-
-
Florence, Itália, 50134
- Recrutamento
- Azienda Ospedaliero Universitaria Careggi
-
Localita La Schiana Pozzuoli, Itália, 80078
- Recrutamento
- ASL Napoli 2 Nord-SM delle Grazie Hospital
-
Milan, Itália, 20141
- Recrutamento
- Istituto Europeo di Oncologia
-
Milan, Itália, 20132
- Recrutamento
- IRCCS Ospedale San Raffaele
-
Roma, Itália, 00144
- Recrutamento
- Istituto Nazionale Tumori Regina Elena
-
Torino, Itália, 10126
- Recrutamento
- Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
-
-
-
-
-
Bunkyō City, Japão, 113 8431
- Recrutamento
- Juntendo University Hospital
-
Hirakata, Japão, 573-1191
- Recrutamento
- Kansai Medical University Hospital
-
Kanazawa, Japão, 920 8641
- Recrutamento
- Kanazawa University Hospital
-
Kobe, Japão, 650 0017
- Recrutamento
- Kobe University Hospital
-
Sagamihara, Japão, 252-0375
- Recrutamento
- Kitasato University Hospital
-
Sunto Gun, Japão, 411 8777
- Recrutamento
- Shizuoka Cancer Center
-
Yokohama, Japão, 232 0024
- Recrutamento
- Yokohama City University Medical Center
-
-
-
-
-
Kota Kinabalu, Malásia, 88996
- Recrutamento
- Hospital Wanita dan Kanak-Kanak Sabah
-
Kuala Lumpur, Malásia, 59100
- Recrutamento
- University Malaya Medical Centre
-
Kuala Lumpur, Malásia, 50586
- Recrutamento
- Hospital Kuala Lumpur
-
Kuala Lumpur, Malásia, 59100
- Recrutamento
- Pantai Hospital Kuala Lumpur
-
Kuching, Malásia, 93586
- Recrutamento
- Hospital Umum Sarawak
-
-
-
-
-
San Juan, Porto Rico, 935
- Recrutamento
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Cardiff, Reino Unido, CF14 2TL
- Recrutamento
- Velindre Cancer Centre
-
Glasgow, Reino Unido, G12 0YN
- Recrutamento
- Beatson West Of Scotland Cancer Centre
-
London, Reino Unido, EC1A 7BE
- Recrutamento
- St Bartholomews Hospital
-
London, Reino Unido, SW3 6JJ
- Recrutamento
- The Royal Marsden NHS Trust
-
Newcastle upon Tyne, Reino Unido, NE7 7DN
- Recrutamento
- The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
-
Preston, Reino Unido, PR2 9HT
- Recrutamento
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
Sutton, Reino Unido, SM2 5PT
- Recrutamento
- Royal Marsden Hospital
-
-
-
-
-
Taichung, Taiwan, 435
- Recrutamento
- Tungs' Taichung MetroHarbor Hospital
-
Taichung, Taiwan, 404
- Recrutamento
- China Medical University Hospital
-
Taichung, Taiwan, 407219
- Recrutamento
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- Recrutamento
- National Cheng Kung University Hospital
-
Taoyuan, Taiwan, 333
- Recrutamento
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Adana, Turquia (Türkiye), 01170
- Recrutamento
- Adana City Hospital
-
Ankara, Turquia (Türkiye), 06010
- Recrutamento
- Gulhane Training and Research Hospital
-
Ankara, Turquia (Türkiye), 06100
- Recrutamento
- Ankara University Medical Faculty
-
Istanbul, Turquia (Türkiye), 34096
- Recrutamento
- Istanbul University Cerrahpasa tip Fakultesi
-
Istanbul, Turquia (Türkiye), 34147
- Recrutamento
- Koc Universitesi Hastanesi
-
Izmir, Turquia (Türkiye), 35170
- Recrutamento
- Medicana International Izmir
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m^Tc bone scan as determined by the investigator
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
- Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion criteria:
- Known history of either brain or leptomeningeal prostate cancer metastases
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
- Prior or concurrent second malignancy (other than the disease under study)
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Pasritamig+Docetaxel
Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met. |
Pasritamig will be administered.
Outros nomes:
Docetaxel will be administered. |
|
Comparador Ativo: Docetaxel
Participants will receive docetaxel along with prednisone/prednisolone as background medication. |
Docetaxel will be administered. Prednisone/Prednisolone will be administered. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
Prazo: Up to approximately 1 years 10 months
|
rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first. |
Up to approximately 1 years 10 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall Survival (OS)
Prazo: Up to approximately 4 years 5 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 4 years 5 months
|
|
Time to Symptomatic Progression (TSP)
Prazo: Up to approximately 4 years 5 months
|
TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms. |
Up to approximately 4 years 5 months
|
|
Time to Subsequent Therapy (TST)
Prazo: Up to approximately 4 years 5 months
|
TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer |
Up to approximately 4 years 5 months
|
|
Time to Skeletal-Related Event (TSRE)
Prazo: Up to approximately 4 years 5 months
|
TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression. |
Up to approximately 4 years 5 months
|
|
Objective Response Rate (ORR)
Prazo: Up to approximately 4 years 5 months
|
ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR. |
Up to approximately 4 years 5 months
|
|
Duration of Response (DOR)
Prazo: Up to approximately 4 years 5 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to approximately 4 years 5 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Prazo: Up to approximately 4 years 5 months
|
Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (>=) 25% and >=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value >=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases >=25% and >=2 ng/mL from baseline after 12 weeks |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response
Prazo: Up to approximately 4 years 5 months
|
PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response
Prazo: Up to approximately 4 years 5 months
|
PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Duration of PSA Response
Prazo: Baseline and up to approximately 4 years 5 months
|
Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by >= 50%. |
Baseline and up to approximately 4 years 5 months
|
|
Progression Free Survival After Subsequent Therapy (PFS2)
Prazo: Up to approximately 4 years 5 months
|
PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first. |
Up to approximately 4 years 5 months
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity
Prazo: Up to approximately 4 years 5 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 4 years 5 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
Prazo: Up to approximately 4 years 5 months
|
Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported. |
Up to approximately 4 years 5 months
|
|
Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
Prazo: Baseline up to approximately 4 years 5 months
|
The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score
Prazo: Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score
Prazo: Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score
Prazo: Baseline up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life. |
Baseline up to approximately 4 years 5 months
|
|
Time to Sustained Worsening of Pain as Assessed by BPI-SF
Prazo: Up to approximately 4 years 5 months
|
Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Up to approximately 4 years 5 months
|
|
Treatment Side Effect as Assessed by EORTC IL46 Score
Prazo: Up to approximately 4 years 5 months
|
The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much". |
Up to approximately 4 years 5 months
|
|
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score
Prazo: Up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life. |
Up to approximately 4 years 5 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças prostáticas
- Doenças Urogenitais Masculinas
- Neoplasias prostáticas
- Neoplasias Prostáticas Resistentes à Castração
- Produtos químicos orgânicos
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Compostos policíclicos
- Taxóides
- Ciclodecanos
- Diterpenos
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Pregadienetriols
- PregadaDiols
- Docetaxel
- Prednisona
- Prednisolona
Outros números de identificação do estudo
- 78278343PCR3003
- 2025-522713-29-00 (Identificador de registro: EUCT number)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .